Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 2
2021 2
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Preclinical therapeutic targets in diffuse midline glioma.
Meel MH, Kaspers GJL, Hulleman E. Meel MH, et al. Drug Resist Updat. 2019 May;44:15-25. doi: 10.1016/j.drup.2019.06.001. Epub 2019 Jun 7. Drug Resist Updat. 2019. PMID: 31202081 Free article. Review.
Diffuse midline gliomas (DMG) are rapidly fatal tumors of the midbrain in children, characterized by a diffuse growing pattern and high levels of intrinsic resistance to therapy. ...We here provide an overview of the cellular pathways and tumor-specifi
Diffuse midline gliomas (DMG) are rapidly fatal tumors of the midbrain in children, characterized by a diffuse g
Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma.
Wierzbicki K, Ravi K, Franson A, Bruzek A, Cantor E, Harris M, Homan MJ, Marini BL, Kawakibi AR, Ravindran R, Teodoro R, Yadav VN, Koschmann C. Wierzbicki K, et al. Curr Oncol Rep. 2020 Feb 6;22(2):19. doi: 10.1007/s11912-020-0877-0. Curr Oncol Rep. 2020. PMID: 32030483 Free PMC article. Review.
PURPOSE OF REVIEW: H3K27M is a frequent histone mutation within diffuse midline gliomas and is associated with a dismal prognosis, so much so that the 2016 CNS WHO classification system created a specific category of "Diffuse Midline Glioma
PURPOSE OF REVIEW: H3K27M is a frequent histone mutation within diffuse midline gliomas and is associated with a dismal …
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM, Richards RM, Jiang L, Barsan V, Mancusi R, Geraghty AC, Good Z, Mochizuki AY, Gillespie SM, Toland AMS, Mahdi J, Reschke A, Nie EH, Chau IJ, Rotiroti MC, Mount CW, Baggott C, Mavroukakis S, Egeler E, Moon J, Erickson C, Green S, Kunicki M, Fujimoto M, Ehlinger Z, Reynolds W, Kurra S, Warren KE, Prabhu S, Vogel H, Rasmussen L, Cornell TT, Partap S, Fisher PG, Campen CJ, Filbin MG, Grant G, Sahaf B, Davis KL, Feldman SA, Mackall CL, Monje M. Majzner RG, et al. Nature. 2022 Mar;603(7903):934-941. doi: 10.1038/s41586-022-04489-4. Epub 2022 Feb 7. Nature. 2022. PMID: 35130560 Free PMC article. Clinical Trial.
Diffuse intrinsic pontine glioma (DIPG) and other H3K27M-mutated diffuse midline gliomas (DMGs) are universally lethal paediatric tumours of the central nervous system(1). We have previously shown that the disialoganglioside GD2 is highly expres
Diffuse intrinsic pontine glioma (DIPG) and other H3K27M-mutated diffuse midline gliomas (DMGs) are unive
Current Murine Models and New Developments in H3K27M Diffuse Midline Gliomas.
Welby JP, Kaptzan T, Wohl A, Peterson TE, Raghunathan A, Brown DA, Gupta SK, Zhang L, Daniels DJ. Welby JP, et al. Front Oncol. 2019 Feb 27;9:92. doi: 10.3389/fonc.2019.00092. eCollection 2019. Front Oncol. 2019. PMID: 30873381 Free PMC article.
Diffuse Midline Gliomas with Histone 3-Lysine-27-Methionine (H3K27M) mutation constitute the majority of Diffuse Intrinsic Pontine Glioma (DIPG), which is the most aggressive form of pediatric glioma with a dire prognosis. ...These models
Diffuse Midline Gliomas with Histone 3-Lysine-27-Methionine (H3K27M) mutation constitute the majority of Diffuse
Inhibition of microglial EZH2 leads to anti-tumoral effects in pediatric diffuse midline gliomas.
Keane L, Cheray M, Saidi D, Kirby C, Friess L, Gonzalez-Rodriguez P, Gerdes ME, Grabert K, McColl BW, Joseph B. Keane L, et al. Neurooncol Adv. 2021 Jul 5;3(1):vdab096. doi: 10.1093/noajnl/vdab096. eCollection 2021 Jan-Dec. Neurooncol Adv. 2021. PMID: 34485907 Free PMC article.
BACKGROUND: Diffuse intrinsic pontine gliomas (DIPG), within diffuse midline gliomas are aggressive pediatric brain tumors characterized by histone H3-K27M mutation. ...Antisense RNA strategies were used to target EZH2 gene expression in …
BACKGROUND: Diffuse intrinsic pontine gliomas (DIPG), within diffuse midline gliomas are aggressive pedia …
Histone-Mutant Glioma: Molecular Mechanisms, Preclinical Models, and Implications for Therapy.
Graham MS, Mellinghoff IK. Graham MS, et al. Int J Mol Sci. 2020 Sep 29;21(19):7193. doi: 10.3390/ijms21197193. Int J Mol Sci. 2020. PMID: 33003625 Free PMC article. Review.
Specific hallmark oncogenic histone mutations within pediatric malignant gliomas divide these tumors into subgroups with different neuroanatomic and chronologic predilections. In this review, we will summarize the characteristic molecular alterations of pediatric high-grad …
Specific hallmark oncogenic histone mutations within pediatric malignant gliomas divide these tumors into subgroups with different ne …
Utilizing preclinical models to develop targeted therapies for rare central nervous system cancers.
Arakaki AKS, Szulzewsky F, Gilbert MR, Gujral TS, Holland EC. Arakaki AKS, et al. Neuro Oncol. 2021 Nov 2;23(23 Suppl 5):S4-S15. doi: 10.1093/neuonc/noab183. Neuro Oncol. 2021. PMID: 34725698 Free PMC article. Review.
Recent technological advances have identified molecular drivers of some of these rare cancers which we can now use to generate representative preclinical models of these diseases. In this review, we outline the advantages and disadvantages of different models, emphasizing …
Recent technological advances have identified molecular drivers of some of these rare cancers which we can now use to generate representativ …
Generation of immunocompetent syngeneic allograft mouse models for pediatric diffuse midline glioma.
du Chatinier A, Meel MH, Das AI, Metselaar DS, Waranecki P, Bugiani M, Breur M, Simonds EF, Lu ED, Weiss WA, Garcia Vallejo JJ, Hoving EW, Phoenix TN, Hulleman E. du Chatinier A, et al. Neurooncol Adv. 2022 May 24;4(1):vdac079. doi: 10.1093/noajnl/vdac079. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 35733514 Free PMC article.
BACKGROUND: Diffuse midline gliomas (DMG) are highly malignant incurable pediatric brain tumors. ...These models adequately recapitulated the histopathology, immune microenvironment, and therapeutic response of human DMG, providing useful tools for fut …
BACKGROUND: Diffuse midline gliomas (DMG) are highly malignant incurable pediatric brain tumors. ...These models adequa …
Venetoclax Cooperates with Ionizing Radiation to Attenuate Diffuse Midline Glioma Tumor Growth.
Madhavan K, Balakrishnan I, Lakshmanachetty S, Pierce A, Sanford B, Fosmire S, Elajaili HB, Walker F, Wang D, Nozik ES, Mitra SS, Dahl NA, Vibhakar R, Venkataraman S. Madhavan K, et al. Clin Cancer Res. 2022 Jun 1;28(11):2409-2424. doi: 10.1158/1078-0432.CCR-21-4002. Clin Cancer Res. 2022. PMID: 35344040
PURPOSE: Tumor relapse after radiotherapy is a major hurdle in treating pediatric H3K27M-mutant diffuse midline gliomas (DMG). Radiotherapy-induced stress increases association of BCL2 family of proteins with BH3 pro-apoptotic activators preventing apoptosis. …
PURPOSE: Tumor relapse after radiotherapy is a major hurdle in treating pediatric H3K27M-mutant diffuse midline gliomas
Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC).
Liguori NR, Sanchez Sevilla Uruchurtu A, Zhang L, Abbas AE, Lee YS, Zhou L, Azzoli CG, El-Deiry WS. Liguori NR, et al. Am J Cancer Res. 2022 Feb 15;12(2):729-743. eCollection 2022. Am J Cancer Res. 2022. PMID: 35261798 Free PMC article.
ONC201/TIC10 is a TRAIL pathway-inducing compound that with demonstrated clinical efficacy in H3K27M-mutated diffuse midline glioma and neuroendocrine tumors, in early phase clinical trials. We hypothesized that combining ONC201 and lurbinectedin may yield sy …
ONC201/TIC10 is a TRAIL pathway-inducing compound that with demonstrated clinical efficacy in H3K27M-mutated diffuse midline